Toxicities of CD19 CAR‐T cell immunotherapy. (6th March 2019)

• Record Type: Journal Article
• Authors: Hirayama, Alexandre V.; Turtle, Cameron J.
• Other Names: Frey Noelle V. guestEditor.; Porter David L. guestEditor.
• Is Part Of: American journal of hematology. Volume 94(2019)Supplement 1
• Page Start: S42
• Page End: S49
• Publication Date: 2019-03-06
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25445
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: CD19‐targeted chimeric antigen receptor (CAR)‐modified T (CAR‐T) cell immunotherapy has demonstrated impressive results in B‐cell malignancies, and CAR‐T cell therapies targeting other antigens are in development for other cancers. Cytokine release syndrome (CRS) and neurotoxicity can be life‐threatening in a subset of patients. The severity of CRS and neurotoxicity can be impacted by the disease burden, lymphodepletion regimen, and CAR‐T cell dose. Tocilizumab and corticosteroids have been used to manage these toxicities, enabling CD19 CAR‐T cells to be administered without obvious compromise in efficacy. Consensus criteria for grading and managing toxicities will facilitate the widespread application of this treatment modality.